New Approach of Anti-VEGF Agents for Age-Related Macular Degeneration

Age-related macular degeneration (AMD) is the leading cause of visual loss in older population. Angiogenesis is an important factor associated with the development of CNV due to AMD. Treatment of CNV with intravitreal anti-VEGF monotherapy is currently the standard of care. However, not all patients...

Full description

Bibliographic Details
Main Authors: Young Gun Park, Hyun Wook Rhu, Seungbum Kang, Young Jung Roh
Format: Article
Language:English
Published: Hindawi Limited 2012-01-01
Series:Journal of Ophthalmology
Online Access:http://dx.doi.org/10.1155/2012/637316
id doaj-6decbf5a13a34ce69ecad3ac9579f63d
record_format Article
spelling doaj-6decbf5a13a34ce69ecad3ac9579f63d2020-11-24T22:30:43ZengHindawi LimitedJournal of Ophthalmology2090-004X2090-00582012-01-01201210.1155/2012/637316637316New Approach of Anti-VEGF Agents for Age-Related Macular DegenerationYoung Gun Park0Hyun Wook Rhu1Seungbum Kang2Young Jung Roh3Department of Ophthalmology, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, No. 62 Yeouido-dong, Yeongdeungpo-gu, Seoul 150-713, Republic of KoreaDepartment of Ophthalmology, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, No. 62 Yeouido-dong, Yeongdeungpo-gu, Seoul 150-713, Republic of KoreaDepartment of Ophthalmology, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, No. 62 Yeouido-dong, Yeongdeungpo-gu, Seoul 150-713, Republic of KoreaDepartment of Ophthalmology, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, No. 62 Yeouido-dong, Yeongdeungpo-gu, Seoul 150-713, Republic of KoreaAge-related macular degeneration (AMD) is the leading cause of visual loss in older population. Angiogenesis is an important factor associated with the development of CNV due to AMD. Treatment of CNV with intravitreal anti-VEGF monotherapy is currently the standard of care. However, not all patients respond to monotherapy, and modified anti-VEGF treatment regimen and combination therapy may target reducing treatment frequency or improving visual outcome. This paper reviews the many clinical trials that have been performed utilizing several treatment regimens. While many trials have shown that this variable therapy is justifiable, further study is required to determine correct regimens and dosage.http://dx.doi.org/10.1155/2012/637316
collection DOAJ
language English
format Article
sources DOAJ
author Young Gun Park
Hyun Wook Rhu
Seungbum Kang
Young Jung Roh
spellingShingle Young Gun Park
Hyun Wook Rhu
Seungbum Kang
Young Jung Roh
New Approach of Anti-VEGF Agents for Age-Related Macular Degeneration
Journal of Ophthalmology
author_facet Young Gun Park
Hyun Wook Rhu
Seungbum Kang
Young Jung Roh
author_sort Young Gun Park
title New Approach of Anti-VEGF Agents for Age-Related Macular Degeneration
title_short New Approach of Anti-VEGF Agents for Age-Related Macular Degeneration
title_full New Approach of Anti-VEGF Agents for Age-Related Macular Degeneration
title_fullStr New Approach of Anti-VEGF Agents for Age-Related Macular Degeneration
title_full_unstemmed New Approach of Anti-VEGF Agents for Age-Related Macular Degeneration
title_sort new approach of anti-vegf agents for age-related macular degeneration
publisher Hindawi Limited
series Journal of Ophthalmology
issn 2090-004X
2090-0058
publishDate 2012-01-01
description Age-related macular degeneration (AMD) is the leading cause of visual loss in older population. Angiogenesis is an important factor associated with the development of CNV due to AMD. Treatment of CNV with intravitreal anti-VEGF monotherapy is currently the standard of care. However, not all patients respond to monotherapy, and modified anti-VEGF treatment regimen and combination therapy may target reducing treatment frequency or improving visual outcome. This paper reviews the many clinical trials that have been performed utilizing several treatment regimens. While many trials have shown that this variable therapy is justifiable, further study is required to determine correct regimens and dosage.
url http://dx.doi.org/10.1155/2012/637316
work_keys_str_mv AT younggunpark newapproachofantivegfagentsforagerelatedmaculardegeneration
AT hyunwookrhu newapproachofantivegfagentsforagerelatedmaculardegeneration
AT seungbumkang newapproachofantivegfagentsforagerelatedmaculardegeneration
AT youngjungroh newapproachofantivegfagentsforagerelatedmaculardegeneration
_version_ 1725739660256215040